Chiral Quest Subsidiary Signs License Agreement with
News Sep 27, 2005
VioQuest's subsidiary Chiral Quest, Inc., (VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the process development and manufacture of single-enantiomer intermediates and active pharmaceutical ingredients.
This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.
Ataxin Links Long Term-Memory and NeurodegenerationNews
Scientists have just discovered that a small region of a cellular protein that helps long-term memories form also drives the neurodegeneration seen in motor neuron disease (MND)READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018